Table 2.
Clinical data.
| HC (n = 30) | RA (n = 30) | SLE (n = 26) | |
|---|---|---|---|
| Age | 34.6 ± 8.0 | 54.5 ± 13.8****a **b | 42.9 ± 15.3 |
| Male/Female–n | 7/23 | 8/22 | 2/24 |
| SLEDAI–median (IQR) | – | – | 8 (9.5) |
| Lupus nephritis–n, (%) | – | – | 5 (19.2) |
| NPSLE–n, (%) | – | – | 8 (30.8) |
| WBC (/μL) | 5,266 ± 1,332 | 7,143 ± 2,171**c | 6,108 ± 2,889 |
| Lymphocyte (/μL) | 1,859 ± 644 | 1,523 ± 576 | 1,284 ± 875 **d |
| CH50 (U/mL) | – | – | 36.2 ± 16.6 |
| Anti-dsDNA antibody (U/mL) | – | – | 87.9 ± 130.2 |
Data are presented as mean ± SD, unless otherwise specified. For SLEDAI, median with interquartile range (IQR). HC, Healthy Control; RA, Rheumatoid Arthritis; SLE, Systemic Lupus Erythematosus; SLEDAI, SLE Disease Activity Index; NPSLE, Neuropsychiatric SLE; WBC, White Blood cell count; CH50, total complement activity; Anti-dsDNA antibody, Anti double stranded DNA antibody.
**
0.001 < P < 0.01,
****
P < 0.0001, Categorical data were tested with Fisher's exact test. Continuous data were tested with Kruskal-Wallis test followed by Dunn's multiple comparison test.
a
High compared with HC,
b
high compared with SLE,
c
high compared with HC,
d
low compared with HC.